Sweden's Active Biotech has doubled the maximum tolerated dose of its experimental prostate therapy in a Phase Ib trial. Researchers increased dosage to 1 mg a day, which can be used in an upcoming mid-stage trial for the drug later this year. Active's stock price was buoyed by the news.
"These new results confirm and reinforce earlier results obtained at a lower dose level. We now have a very complete data set that constitute a solid base to move into Phase II clinical trials", said Active Biotech CEO Sven Andréasson.
- see the release on the trial data